OBJECTIVE： To provide reference for the rational use of narcotic drugs. METHODS： The utilization of narcotic drugs for inpatients in our hospital during 2012-2014 were collected from HIS， and analyzed statistically in respects of consumption amount， consumption sum， DDDs， B/A， DDC and consumption amount of the different departments， and so on. RESULTS： The quantity and consumption amount of Morphine sulfate sustained-release tablets， Oxycodone hydrochloride sustained-release tablets and Codeine phosphate tablet ranked the first 3 places during 2012-2014. Morphine sulfate sustained-release tablets， Oxycodone hydrochloride sustained-release tablets and Fentanyl transdermal patch （8.4 mg） steadily occupied the first 3 places in the list of consumption sum. In the list of DDDs， Fentanyl transdermal patch and Morphine sulfate sustained-release tablets took up the first 3 places； Morphine hydrochloride injection， Bucinnazine hydrochloride injection and Meperidine hydrochloride injection occupied the last 3 places. B/A value of Morphine sulfate sustained-release tablets and Fentanyl transdermal patch （8.4 mg）  in 2012， Oxycodone hydrochloride sustained-release tablets in 2014， Fentanyl transdermal patch （2.5 mg） in 2013 and 2014 were all equal to 1 and synchronized well. Others were all biased. DDC of narcotic drugs kept stable in 3 years， and DDC of Oxycodone hydrochloride sustained-release tablets took up the first place， followed by Fentanyl transdermal patch （8.4 mg）. Narcotic drugs were consumed in 19 departments， but mainly in the department of oncology and general surgery. In the department of oncology， the consumption amount and sum of oral formulation were both significantly higher than other dosage forms， accounting for more than 88％ and 52％ respectively. CONCLUSIONS： The variety and dosage form of narcotic drugs could meet the clinical needs and its application is basically reasonable. Besides， the utilization of narcotic drugs in the department of oncology consistent with the basic principles of WHO three steps cancer analgesia treatments.